$GKOS

WEN LEANA sold $88K of GKOS

WEN LEANA sold 525 shares of GLAUKOS Corp (GKOS) at $167.63 on 2026-07-31.

Original reporting
SEC EDGAR · WEN LEANA
Published Aug 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest fact is the reported open-market sale size, price, and post-transaction holdings for a director. It does not include any operational or financial guidance changes.

02

Market read

Traders may note insider selling for sentiment monitoring, but the disclosed value (~$88K) is unlikely to be a standalone catalyst.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says none), but it also provides no context on total holdings, prior sales cadence, or reasons for the transaction.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-03, transaction dated 2026-07-31.

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp (GKOS).

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos director Wen Leana filed a Form 4 open-market sale of 525 shares at $167.63 on 2026-07-31, worth about $88K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying corporate news, guidance, or operational catalyst in the text.

Market effects

No sector read-through is provided beyond a routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or planned liquidity needs and may not signal reduced confidence.

Key entities

  • GLAUKOS Corp

    Company whose director insider sale is disclosed via Form 4.

  • WEN LEANA

    Director reporting an open-market sale of 525 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.